This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy | MicrobiomeTrials
← Back to trials NCT03952598
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy SUSPENDED PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2019-10-16Est. Completion: 2027-12-31
Enrollment target: 42 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Diffuse Intrinsic Pontine Glioma or Glioblastoma
This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and dif…
Shenzhen, China Completed May 31, 2029
Recurrent Glioblastoma Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Relapsed Cancer Recurrent Tumor Glioblastoma Multiforme Recurring Glioblastoma Brain and Central Nervous System Tumors
Glioma
Glioblastomas
Grade IV Astrocytoma
GBM
Recurrent Glioma (Glioblastoma Multiforme)
High Grade Glioma
Glioma, Malignant
Brain Cancer
Background:
Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. B…
Bethesda, United States Est. completion Dec 31, 2030
IDH-Wildtype Glioblastoma Glioblastoma (GBM)
The body's biological functions follow a circadian rhythm, meaning that individual biological functions in the body chan…
London, Canada Est. completion May 2027